Functional Activity of Cd34-Positive Cells in Chronic Myeloid Leukemia Patients With Different Response to Imatinib Therapy

Sviezhentseva, I.; Perekhrestenko, T.; bilko, Denys; Gordienko, A. I.; Дяченко, М. В.; Dyagil, Iryna

doi:10.31768/2312-8852.2015.37(1):70-72

Cited by 8 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study (12), the results of flow cytometry analysis showed that in patients with the acquisition of resistance to imatinib the number of CD34+ cells increases in the bone marrow and peripheral blood.…”

Section: Discussionmentioning

confidence: 94%

Flow Cytometric Analysis of Chronic Phase Chronic Myeloid Leukemia Patients

Davutoglu¹,

Gündüz²,

Yaman³

et al. 2021

Osmangazi̇ Journal of Medicine

View full text Add to dashboard Cite

Bone marrow aspirate for morphology and cytogenetics and qualitative reverse transcriptase polimerase chain reaction on peripheral blood cells is mandatory for the diagnosis of chronic myeloid leukemia (CML). Bone marrow biopsy and fluorescence in situ hybridisation may be necessary in selected patients. Performing other tests and diagnostic procedures depends on characteristics of the individual patient. Although flow cytometry is an essential tool in the diagnosis and monitoring of many hematological malignancies, it has a limited role in CML. In this study, we evaluated the CD45 side scatter results of our CML patients at diagnosis and during follow up. Totally 56 CML patients (22 female and 34 male) in chronic phase treated with imatinib were included. Patients were also evaluated after 8 (3-19) months follow up. Complete blood cound parameters and CD45/SSC results of the patients at diagnosis and follow up were evaluated retrospectively. The Wilcoxon T test was used to compare the means between the two groups. p<0.05 was considered statistically significant. All of them had decreased leukocyte and platelet counts. There was no difference in hemoglobin value. Comparison of CD45/SSC results at diagnosis and follow up revealed a decrease in granulocyte and blast percentages, and an increase in lymphocyte, monocyte, normoblast percentages. Complete blood counts and CD45/SSC results were not different when we divided patients into 2 groups according to being MMR positive or MMR negative. Survival of MMR positive and negative patients were also found similar. According to the results of our study, we were unable to suggest using CD45/SSC as a routine diagnostic and/or follow up tool. However, there were limitations of our study such as the limited number of patients, the variance between the time of MMR evaluation and the evaluation at only one time point. The results may change in larger studies with serial CD45/SSC analysis and with different tyrosine kinase inhibitors.

show abstract

Section: Discussionmentioning

confidence: 94%

Flow Cytometric Analysis of Chronic Phase Chronic Myeloid Leukemia Patients

Davutoglu¹,

Gündüz²,

Yaman³

et al. 2021

Osmangazi̇ Journal of Medicine

View full text Add to dashboard Cite

show abstract

“…CML is a myeloproliferative neoplasm characterized by the expansion of the early hematopoietic progenitor cells pool which express CD34 antigen [ 31 ]. CML cells were differentiated from other hematopoietic cells based on the intensity of green fluorescence signals emitted by the CD34 antibody (Fig.…”

Section: Resultsmentioning

confidence: 99%

Three-dimensional nuclear telomere architecture and differential expression of aurora kinase genes in chronic myeloid leukemia to measure cell transformation

et al. 2022

View full text Add to dashboard Cite

Background Telomere dysfunction results in aneuploidy, and ongoing chromosomal abnormalities. The three-dimensional (3D) nuclear organization of telomeres allows for a distinction between normal and tumor cells. On the other hand, aurora kinase genes (AURKA and AURKB) play an important role regulating the cell cycle. A correlation between overexpression of aurora kinase genes and clinical aggressiveness has been demonstrated in different types of neoplasias. To better understand cellular and molecular mechanisms of CML evolution, it was examined telomere dysfunction (alterations in the 3D nuclear telomere architecture), and the expression levels of AURKA and AURKB genes in two clinical distinct subgroups of CML samples, from the same patient. Methods Eighteen CML patients, in total, 36 bone marrow samples (18 patients, chronic vs. accelerated/blast phase) were eligible for 3D telomeric investigations. Quantitative 3D imaging, cytologic diagnosis and cytogenetic determination of additional chromosomal abnormalities were assessed according to standard protocols. Results Using TeloView software, two CML subgroups were defined based on their 3D telomeric profiles, reflecting the different stages of the disease (chronic vs. accelerated/blast phase). Statistical analyses showed significant differences between the CML subgroups (p < 0.001). We also found that AURKA and AURKB mRNA were expressed at significantly higher levels in both CML subgroups, when compared with healthy donors. Our findings suggest that the evolution of CML progresses from a low to a high level of telomere dysfunction, that is, from an early stage to a more aggressive stage, followed by disease transformation, as demonstrated by telomere, additional chromosomal abnormalities, and gene expression profile dynamics. Conclusions Thus, we demonstrated that 3D telomere organization, in accordance with the genomic instability observed in CML samples were able to distinguish subgroup CML patients. Classifying CML patients based on these characteristics might represent an important strategy to define better therapeutic strategies.

show abstract

“…CML is a myeloproliferative neoplasm characterized by the expansion of the early hematopoietic progenitor cells pool which express CD34 antigen [31]. CML cells were differentiated from other hematopoietic cells based on the intensity of green uorescence signals emitted by the CD34 antibody (Fig.…”

Section: Resultsmentioning

confidence: 99%

Three-dimensional nuclear telomere architecture and differential expression of aurora kinase genes in chronic myeloid leukemia to measure cell transformation

Oliveira

Jamur

Merfort

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Telomere dysfunction results in aneuploidy, and ongoing chromosomal abnormalities. The three-dimensional (3D) nuclear organization of telomeres allows for a distinction between normal and tumor cells. On the other hand, aurora kinase genes (AURKA and AURKB) play an important role regulating the cell cycle. A correlation between overexpression of aurora kinase genes and clinical aggressiveness has been demonstrated in different types of neoplasias. To better understand cellular and molecular mechanisms of CML evolution, it was examined telomere dysfunction (alterations in the 3D nuclear telomere architecture), and the expression levels of AURKA and AURKB genes in two clinical distinct subgroups of CML samples, from the same patient. Methods: Eighteen CML patients, in total, 36 bone marrow samples (18 patients, chronic vs. accelerated/blast phase) were eligible for 3D telomeric investigations. Quantitative 3D imaging, cytologic diagnosis and cytogenetic determination of additional chromosomal abnormalities were assessed according to standard protocols. Results: Using TeloView software, two CML subgroups were defined based on their 3D telomeric profiles, reflecting the different stages of the disease (chronic vs. accelerated/blast phase). Statistical analyses showed significant differences between the CML subgroups (p<0.001). We also found that AURKA and AURKB mRNA were expressed at significantly higher levels in both CML subgroups, when compared with healthy donors. Our findings suggest that the evolution of CML progresses from a low to a high level of telomere dysfunction, that is, from an early stage to a more aggressive stage, followed by disease transformation, as demonstrated by telomere, additional chromosomal abnormalities, and gene expression profile dynamics. Conclusions: Thus, we demonstrated that 3D telomere organization, in accordance with the genomic instability observed in CML samples were able to distinguish subgroup CML patients. Classifying CML patients based on these characteristics might represent an important strategy to define better therapeutic strategies.

show abstract

Functional Activity of Cd34-Positive Cells in Chronic Myeloid Leukemia Patients With Different Response to Imatinib Therapy

Cited by 8 publications

References 10 publications

Flow Cytometric Analysis of Chronic Phase Chronic Myeloid Leukemia Patients

Flow Cytometric Analysis of Chronic Phase Chronic Myeloid Leukemia Patients

Three-dimensional nuclear telomere architecture and differential expression of aurora kinase genes in chronic myeloid leukemia to measure cell transformation

Three-dimensional nuclear telomere architecture and differential expression of aurora kinase genes in chronic myeloid leukemia to measure cell transformation

Contact Info

Product

Resources

About